This study enrolls high-risk patients without a history of ASCVD, provided they have an Lp(a) level of ≥175 nmol/L and have 3 risk enhancers such as elevated CAC score, elevated hs-CRP, or diabetes. The gene discussed is CRP; the disease is diabetes mellitus.